Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTAFR | P25105 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411448 | 1.00 | LMNA (0.56) | LMNAKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL21100177 | 0.88 | LMNA (0.41) | LMNAKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL21045178 | 0.81 | KDM4E (0.55) | KMT2APOLBPPARGCNR1ALDH1A1 | |
| SCHEMBL29411410 | 0.81 | KDM4E (0.55) | KMT2APOLBPPARGCNR1ALDH1A1 | |
| SCHEMBL21100176 | 0.81 | LMNA (0.39) | LMNAKMT2AMEN1HTTSMN1; SMN2 | |
| SCHEMBL29411419 | 0.76 | EPHX2 (0.48) | KMT2ASMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL29411418 | 0.76 | GABRA5 (0.47) | KMT2APPARGALDH1A1MAPTL3MBTL1 | |
| SCHEMBL21045312 | 0.76 | GABRA5 (0.47) | KMT2APPARGALDH1A1MAPTL3MBTL1 | |
| SCHEMBL21045182 | 0.76 | EPHX2 (0.48) | KMT2ASMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL5420363 | 0.73 | ALDH1A1 (0.60) | LMNAKMT2AMEN1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-20220089539-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2022-03-24 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| US-11040945-B2 | Tubulin inhibitors | LIN BIOSCIENCE PTY LTD. | 2021-06-22 | — | — | US | disclosed |
| WO-2019113242-A1 | TUBULIN INHIBITORS | Lin BioScience, LLC (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
| US-20190169127-A1 | TUBULIN INHIBITORS | LIN BIOSCIENCE INC. (TW) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089539-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | LMNA 2547/4885KMT2A 2339/4885MEN1 955/4885 |
| US-11040945-B2 | Tubulin inhibitors | TUBB3, TUBB1, TUBB | LMNA 2547/4885KMT2A 2339/4885MEN1 955/4885 |
| US-20190169127-A1 | TUBULIN INHIBITORS | TUBB3, TUBB1, TUBB | LMNA 2547/4885KMT2A 2339/4885MEN1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.